News & Media
What’s Next for COVID-19 Vaccines? Hear from the Experts
On Wednesday, August 27, 2025, U.S. Food and Drug Administration (FDA) approved the updated 2025-26 COVID-19 vaccines and rescinded EUAs for COVID-19 vaccines.
The rescission of 2024-25 COVID-19 EUAs means a provider should no longer use that specific COVID-19 vaccine product or presentation. If a provider has a COVID-19 vaccine product previously authorized under an EUA, the vaccine should be removed from the storage unit and properly disposed. Vaccines for Children (VFC) providers should dispose of the COVID-19 vaccine product under EUA following programmatic and the Michigan Care Improvement Registry vaccine wastage guidelines. COVID-19 vaccine products that were listed under EUA are:
- Pfizer-BioNTech COVID-19 Vaccine:
- 6 months through 4 years (multiple dose vials with yellow caps and labels with yellow borders).
- 5 years through 11 years (single dose vials with blue caps and labels with blue borders).
- Moderna COVID-19 Vaccine:
- 6 months through 11 years (manufacturer-filled syringe, 0.25mL).
- Novavax COVID-19 Vaccine:
- 12 years of age and older (manufacturer-filled syringe, 0.5mL).
Key Takeaways:
- The U.S. Food and Drug Administration (FDA) approved updated 2025-26 COVID-19 vaccines for individuals 65 years of age and older and for those 6 months through 64 years old with certain underlying conditions.
- FDA also rescinded Emergency Use Authorizations (EUAs) for certain products. 2024-25 COVID-19 vaccines under an EUA should no longer be used.
- The Advisory Committee on Immunization Practices (ACIP) is scheduled to meet September 18-19, 2025. https://public-inspection.federalregister.gov/2025-16706.pdf
REGISTER NOW!
Thursday, September 11, 2025 • 12:00pm
Join Natasha Bagdasarian, MD, MPH, FIDSA, FACP, Chief Medical Executive, State of Michigan - for a timely session that will provide internal medicine physicians with critical updates on vaccination rates across the state, highlighting progress, disparities, and ongoing public health efforts to improve immunization coverage. Attendees will gain insights into state-level strategies aimed at increasing vaccine uptake and addressing barriers in diverse patient populations. Attendees will leave with an up-to-date understanding of both the public health and policy contexts shaping vaccine administration in Michigan and beyond.